Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma.
Ong SY, Lim JQ, Grigoropoulos N, Laurensia Y, Huang D, Chia BKH, Zhe DCM, Saraf SA, Cheng CL, Chuang WY, Kuo MC, Su YJ, Phipps C, Nagarajan C, Lee YS, Lung DTC, Shih LY, Goh YT, Lim ST, Ong CK. Ong SY, et al. Among authors: nagarajan c. Haematologica. 2021 Jun 1;106(6):1737-1739. doi: 10.3324/haematol.2020.269209. Haematologica. 2021. PMID: 33054138 Free PMC article. No abstract available.
Thrombotic microangiopathy during carfilzomib use: case series in Singapore.
Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, Phipps C, Lee YS, Grigoropoulos NF, Lao Z, Surendran S, Teh EM, Goh YT, Chng WJ, Gopalakrishnan SK. Chen Y, et al. Among authors: nagarajan c. Blood Cancer J. 2016 Jul 29;6(7):e450. doi: 10.1038/bcj.2016.62. Blood Cancer J. 2016. PMID: 27471866 Free PMC article. No abstract available.
The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.
Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, Tang T, Goh AZ, Ghosh A, Ng HJ, Gopalakrishnan S, Loh Y, Lim ST, Hwang W, Tan D, Goh YT. Phipps C, et al. Among authors: nagarajan c. Leuk Lymphoma. 2018 Oct;59(10):2336-2341. doi: 10.1080/10428194.2017.1422863. Epub 2018 Jan 18. Leuk Lymphoma. 2018. PMID: 29345210
Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia.
Ong SY, Phipps C, Nagarajan C, Tang T, Lim ST, Goh YT, Lee YS. Ong SY, et al. Among authors: nagarajan c. Leuk Lymphoma. 2020 Jan;61(1):225-227. doi: 10.1080/10428194.2019.1648805. Epub 2019 Aug 5. Leuk Lymphoma. 2020. PMID: 31379229 No abstract available.
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, Ong SY, Xu M; SGHMM1 Investigators; Chng WJ, Goh YT, Nagarajan C. Chen Y, et al. Among authors: nagarajan c. Blood Cancer J. 2021 Sep 3;11(9):150. doi: 10.1038/s41408-021-00544-x. Blood Cancer J. 2021. PMID: 34480015 Free PMC article. Clinical Trial. No abstract available.
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, Low ZS, Prasannan P, Gong C, Tan MGK, Nagarajan C, Huang D, Lu PW, Lim JQ, Barrans S, Ong CK, Lim ST, Chng WJ, Follows G, Hodson DJ, Du MQ, Goh YT, Tan SH, Grigoropoulos NF, Verma NK. Kizhakeyil A, et al. Among authors: nagarajan c. Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0. Mol Cancer. 2021. PMID: 34654425 Free PMC article. No abstract available.
47 results